本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 2025年10月27-28日，四川科伦药业股份有限公司（以下简称"公司"或"四 川科伦"）及子公司参加了国家组织药品联合采购办公室（以下简称"联采办"） 组织的第十一批全国药品集中采购的投标工作。公司产品拟中标本次集中采购， 现将相关情况公告如下： | 序 | 拟中标 | 拟中标品种 | 适应症（要点） | 规格 | 包装数量 | 拟中选价格 | | --- | --- | --- | --- | --- | --- | --- | | 号 | 企业 | | | | | | | 1 | 四川科伦 | 马来酸阿伐 曲泊帕片 | 适用于择期行诊断性操作或 者手术的慢性肝病相关血小 | 20mg | 20mg*10 片/盒 | 49 元/盒 | | | | | 板减少症的成年患者。 适用于既往对糖皮质激素、 | | | | | 2 | 四川科伦 | 艾曲泊帕乙 醇胺片 | 免疫球蛋白等治疗反应不佳 的成人和 12 岁及以上儿童 | 25mg | 25mg*28 片/盒 | 117 元/盒 | | | | | 慢性免疫性(特 ...

Core Viewpoint - The company and its subsidiaries participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement, with several products expected to win bids [1] Group 1: Products and Sales Revenue - The products expected to win bids include Malate Avacopan Tablets, Acalabrutinib Ethanolamine Tablets, Compound Sodium Acetate Ringer's Injection, and Agomelatine Tablets [1] - The projected sales revenue for Acalabrutinib Ethanolamine Tablets in 2024 is 19.94 million yuan [1] - The sales revenue for Compound Sodium Acetate Ringer's Injection is 17.73 million yuan for 2023 and 7.93 million yuan for 2024 [1]

Group 1 - The core point of the article is the performance and changes in the top holdings of the Yinhua CSI Innovation Drug Industry ETF, which reported a net value growth rate of 24.54% over the past year [1] - The fund has added new top holdings including Kanglong Chemical and Baile Tianheng, while increasing its stake in WuXi AppTec by 64.87 million shares, making it the largest holding [1] - The fund has exited from its previous top holdings, including Tigermed and Tonghua Golden Horse [1] Group 2 - The detailed data shows the number of shares held and market value for each of the top holdings, with WuXi AppTec holding 15.52 million shares valued at 1.74 billion and Kanglong Chemical holding 8.56 million shares valued at 306 million [1] - Other significant holdings include Hengrui Medicine, Changchun High-tech, and Kelun Pharmaceutical, with respective increases in shareholding [1] - The report indicates a strategic shift in the fund's portfolio, reflecting a focus on companies with strong growth potential in the pharmaceutical sector [1]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it is expected to outperform the overall market [32]. Core Insights - The report highlights that the Shenwan Pharmaceutical and Biological Index increased by 0.6% this week, while the Shanghai Composite Index rose by 2.9% and the Wind All A (excluding financials and petrochemicals) increased by 3.7% [4][6]. - The pharmaceutical sector's overall valuation stands at 30.4 times earnings, ranking 9th among 31 Shenwan primary industries [4][8]. - Significant collaborations and clinical trial results were reported, including a $11.4 billion global strategic partnership between Innovent Biologics and Takeda Pharmaceutical, which includes a $1.2 billion upfront payment [5][13]. - Key clinical trial results presented at the 2025 ESMO conference showed promising outcomes for several drugs, indicating advancements in treatment efficacy for various cancers [14][18][19]. Market Performance - The report details the performance of various sub-sectors within the pharmaceutical industry, with notable increases in medical devices (+0.2%), medical consumables (+1.7%), and medical research outsourcing (+5.5%), while traditional Chinese medicine and other biological products saw declines [4][8]. - The report also notes that 99 A-share pharmaceutical companies released their Q3 2025 earnings, with a total revenue of 94.15 billion yuan, reflecting a 1.3% year-on-year increase [20][22]. Key Events - The report mentions that Bairui Tianheng has passed the Hong Kong Stock Exchange hearing and is in the process of listing its H-shares [12]. - The report emphasizes the importance of the 2025 ESMO conference, where several companies presented significant clinical data, enhancing their market visibility and potential investment attractiveness [14][17][18]. Company Recommendations - The report recommends focusing on innovative drug sectors and companies with improving performance in medical devices and upstream sectors, including companies like Hengrui Medicine, Changchun High-tech, and Mindray Medical [5][20].

Core Viewpoint - On October 23, 2023, Kelun Pharmaceutical experienced a decline of 3.04% in stock price, with a trading volume of 362 million yuan, indicating market volatility and investor sentiment towards the company [1]. Financing and Trading Activity - On the same day, Kelun Pharmaceutical had a financing buy-in amount of 47.32 million yuan and a financing repayment of 34.36 million yuan, resulting in a net financing buy of 12.96 million yuan. The total financing and securities balance reached 936 million yuan [1]. - The current financing balance of 933 million yuan represents 1.68% of the circulating market value, which is above the 60th percentile level over the past year, indicating a relatively high financing level [1]. - In terms of securities lending, 5,900 shares were repaid, and 10,200 shares were sold short, amounting to 355,000 yuan at the closing price. The remaining short-selling volume was 80,000 shares, with a balance of 2.784 million yuan, which is below the 50th percentile level over the past year, suggesting a lower level of short interest [1]. Company Financial Performance - As of June 30, 2025, Kelun Pharmaceutical reported a total revenue of 9.083 billion yuan for the first half of the year, reflecting a year-on-year decrease of 23.20%. The net profit attributable to shareholders was 1.001 billion yuan, down 44.41% compared to the previous year [2]. - Since its A-share listing, Kelun Pharmaceutical has distributed a total of 6.898 billion yuan in dividends, with 3.587 billion yuan distributed over the past three years [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Kelun Pharmaceutical reached 34,200, an increase of 2.55% from the previous period. The average number of circulating shares per shareholder decreased by 2.49% to 38,138 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A (003095) by 12.6942 million shares, while Hong Kong Central Clearing Limited reduced its holdings by 2.7086 million shares [3].

Core Insights - The 2025 Sichuan Top 100 Enterprises list was released, showing a total of 8 companies with revenues exceeding 100 billion yuan, an increase of 3 from 2024 [1] - Tongwei Group Limited topped the list with revenues surpassing 200 billion yuan, marking its first time at the top [1] - Sichuan Energy Development Group and Qiya Group entered the 100 billion yuan revenue club for the first time [1] Company Rankings - Tongwei Group Limited: Revenue of 24,137,998 million yuan [2] - Sichuan Yibin Wuliangye Group Limited: Revenue of 19,529,677 million yuan [2] - Sichuan Changhong Electronics Holding Group Limited: Revenue of 15,267,474 million yuan [2] - Sichuan Energy Development Group Limited: Revenue of 11,745,767.72 million yuan [2] - Qiya Group Limited: Revenue of 11,035,872.53 million yuan [2] - New Hope Liuhe Co., Ltd.: Revenue of 10,306,296.23 million yuan [2] - Luzhou Laojiao Group Limited: Revenue of 10,045,283.6 million yuan [2] - Sichuan Huaxi Group Limited: Revenue of 10,010,347.8 million yuan [2] Additional Rankings - Sichuan Chuanwei Group Limited: Revenue of 8,871,760 million yuan [4] - China National Petroleum Corporation Sichuan Sales Branch: Revenue of 8,830,342.77 million yuan [4] - China Wuyi Group Limited: Revenue of 8,003,938.45 million yuan [4] - Blue Run Group Limited: Revenue of 7,855,709.32 million yuan [4] - China Dongfang Electric Group Limited: Revenue of 7,555,541.23 million yuan [4]

Core Viewpoint - The Medical Health Index (980016) closed at 6646.6 points, down 0.3%, with a trading volume of 19.922 billion yuan and a turnover rate of 0.75% on October 23 [1] Group 1: Index Performance - Among the constituent stocks of the Medical Health Index, 16 stocks rose while 31 stocks fell, with Kanglong Chemical leading the gainers at 1.55% and Te Bao Biological leading the decliners at 6.07% [1] - The top ten constituent stocks of the Medical Health Index include: - WuXi AppTec (14.37% weight, latest price 101.90, market cap 304.045 billion yuan) - Hengrui Medicine (11.45% weight, latest price 65.14, market cap 432.347 billion yuan) - Mindray Medical (8.07% weight, latest price 221.80, market cap 268.920 billion yuan) [1] Group 2: Capital Flow - The net outflow of main funds from the constituent stocks of the Medical Health Index totaled 1.072 billion yuan, while retail investors saw a net inflow of 955 million yuan [3] - Detailed capital flow for key stocks includes: - Mindray Medical: Main net inflow of 66.9479 million yuan, retail net inflow of 3.6088 million yuan - Te Bao Biological: Main net inflow of 29.0966 million yuan, retail net outflow of 41.3737 million yuan [3]

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. announced significant clinical research results from its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., at the 2025 European Society for Medical Oncology (ESMO) conference, highlighting advancements in targeted antibody-drug conjugates (ADCs) for various cancers [1]. Group 1: Clinical Research Results Overview - Two studies on sac-TMT (LKB5) were selected for Late Breaking Abstract (LBA) oral presentations, demonstrating its efficacy in treating EGFR mutation-positive non-small cell lung cancer (NSCLC) and hormone receptor-positive, HER2-negative breast cancer (BC) [2][3]. - In the OptiTROP-Lung04 study, sac-TMT showed a median progression-free survival (PFS) of 8.3 months compared to 4.3 months for chemotherapy, reducing the risk of disease progression or death by 51% [2][3]. - The OptiTROP-Breast02 study reported a median PFS of 8.3 months for sac-TMT versus 4.1 months for investigator's choice chemotherapy, with a hazard ratio (HR) of 0.35 [4][5]. Group 2: Safety and Efficacy - Both studies indicated similar rates of treatment-related adverse events (TRAEs) between sac-TMT and chemotherapy, with no TRAEs leading to treatment discontinuation in the sac-TMT group [3][5]. - The objective response rate (ORR) for sac-TMT was 60.6% in NSCLC and 41.5% in BC, significantly higher than the chemotherapy groups [2][5]. - The studies support the approval of sac-TMT by the National Medical Products Administration (NMPA) for specific cancer treatments [3][5]. Group 3: Additional Research and Drug Information - The study on SKB315, targeting Claudin18.2 in advanced solid tumors, showed an ORR of 37.5% and a median PFS of 8.2 months [6]. - The innovative drugs sac-TMT and botu-tuzumab (舒泰莱) are designed to target specific cancer types, with sac-TMT being the first TROP2 ADC approved for lung cancer indications [8][10]. - Kelun Botai has initiated multiple clinical studies for these drugs, indicating a robust pipeline for cancer treatment [9][11].

Core Points - The Medical Health R Index (480016) closed at 7852.45 points, up 1.04%, with a trading volume of 22.052 billion yuan and a turnover rate of 0.74% [1] - Among the index constituents, 40 stocks rose while 9 fell, with WuXi AppTec leading the gainers at 4.27% and Pian Zai Huang leading the decliners at 0.91% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (603259) with a weight of 14.37%, latest price at 102.04, and a market cap of 304.463 billion yuan [1] - Hengrui Medicine (600276) with a weight of 11.45%, latest price at 66.00, and a market cap of 438.055 billion yuan [1] - Mindray Medical (300760) with a weight of 8.07%, latest price at 223.57, and a market cap of 271.066 billion yuan [1] - United Imaging Healthcare (688271) with a weight of 4.32%, latest price at 143.03, and a market cap of 117.879 billion yuan [1] - Pian Zai Huang (600436) with a weight of 3.59%, latest price at 185.38, and a market cap of 111.843 billion yuan [1] - Aier Eye Hospital (300015) with a weight of 3.21%, latest price at 12.33, and a market cap of 114.982 billion yuan [1] - Kelun Pharmaceutical (002422) with a weight of 2.54%, latest price at 36.05, and a market cap of 57.610 billion yuan [1] - Changchun High & New Technology (000661) with a weight of 2.35%, latest price at 120.28, and a market cap of 49.067 billion yuan [1] - Fosun Pharma (600196) with a weight of 2.28%, latest price at 29.28, and a market cap of 78.190 billion yuan [1] - Sinopharm (002001) with a weight of 2.22%, latest price at 23.27, and a market cap of 71.519 billion yuan [1] Capital Flow Analysis - The net inflow of main funds into the Medical Health R Index constituents totaled 634 million yuan, while retail funds saw a net outflow of 105 million yuan [1] - Detailed capital flow for key stocks includes: - WuXi AppTec with a net inflow of 353.9 million yuan from main funds [2] - Sinopharm with a net inflow of 90.036 million yuan from main funds [2] - Hengrui Medicine with a net inflow of 76.418 million yuan from main funds [2] - Other stocks like Changchun High & New Technology and Fosun Pharma also experienced varying levels of net inflow and outflow [2]

Core Insights - The approval of the new drug injection trastuzumab botidotin by Kelun Pharmaceutical marks a significant milestone in the company's product portfolio, targeting HER2-positive breast cancer patients who have previously undergone treatment [1][3] - Kelun Pharmaceutical's launch of the rotigotine patch represents the first domestic generic version of a drug that has dominated the Parkinson's disease treatment market, breaking the original manufacturer's monopoly [6][9] - The company has demonstrated a strong performance in the pharmaceutical sector, with over 40 generic drugs approved this year, enhancing its competitiveness in both domestic and international markets [11] Drug Approvals - The injection trastuzumab botidotin is a HER2 ADC monoclonal antibody developed by Kelun Biotech, approved for patients with unresectable or metastatic HER2-positive breast cancer who have received prior HER2-targeted therapies [3] - The rotigotine patch, originally developed by UCB Pharma, is the first transdermal patch for treating Parkinson's disease, with global sales exceeding $300 million in 2023, accounting for approximately 22% of the market share for Parkinson's treatments [6][9] Market Position - Kelun Pharmaceutical has successfully launched two ADC drugs, trastuzumab botidotin and another drug, enhancing its position in the ADC market, which is a key focus area for the company [4] - The approval of the rotigotine patch not only diversifies Kelun's product offerings but also positions the company as a significant player in the Parkinson's disease treatment market, previously dominated by UCB Pharma [6][9] Clinical Development - Kelun has a robust pipeline with nine ADC drugs in various stages of clinical trials, indicating a strong commitment to innovation and development in the oncology sector [4] - The company has also received approvals for additional new drugs, including injection formulations that further expand its therapeutic range [11]